CJC-1295 with DAC binds albumin, extending its half-life to 5 to 8 days
A Nature Medicine review published in January 2026 described GLP-1 medicines as "being prescribed to growing numbers of patients worldwide" for an expanding list of indications and noted that "new, more effective molecules with optimised pharmacokinetics produce greater weight loss and some may be more effective for various metabolic disorders, through incorporation of one or more additional peptide epitopes." The clinical pipeline includes 39 GLP-1 receptor agonist drugs in development across 34 companies, with only seven coming from the top 20 pharmaceutical firms
Track your peptide clearance with the peptide half-life tracker
Tailoring a Functional Synthetic Microbial Community Alleviates Fusobacterium nucleatum-infected Colorectal Cancer via Ecological Control
Study methods: Adult patients who were taking GLP-1s and scheduled to receive anesthesia at 3 hospitals between June 30, 2023, and August 15, 2024, were evaluated via preoperative point-of-care gastric ultrasonography (GUS)
The SFN extract was found to be highly effective in blocking the activity of inactivation of an oncogenic factor pSTAT3